OXIA Stock Overview
A clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
GT Biopharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.77 |
| 52 Week High | US$10.74 |
| 52 Week Low | US$4.77 |
| Beta | 0.57 |
| 1 Month Change | 0% |
| 3 Month Change | -9.66% |
| 1 Year Change | -48.71% |
| 3 Year Change | -98.53% |
| 5 Year Change | n/a |
| Change since IPO | -96.48% |
Recent News & Updates
Recent updates
Shareholder Returns
| OXIA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.8% | 0.6% |
| 1Y | -48.7% | -3.9% | 13.3% |
Return vs Industry: OXIA underperformed the German Biotechs industry which returned -21.6% over the past year.
Return vs Market: OXIA underperformed the German Market which returned 2.2% over the past year.
Price Volatility
| OXIA volatility | |
|---|---|
| OXIA Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: OXIA's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine OXIA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1965 | 2 | Michael Breen | www.gtbiopharma.com |
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors.
GT Biopharma, Inc. Fundamentals Summary
| OXIA fundamental statistics | |
|---|---|
| Market cap | €3.89m |
| Earnings (TTM) | -€7.13m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs OXIA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OXIA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$7.60m |
| Earnings | -US$7.60m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.50 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did OXIA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/05/01 01:03 |
| End of Day Share Price | 2024/02/02 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
GT Biopharma, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Justin Walsh | B. Riley Securities, Inc. |
| Charles Butler | Roth Capital Partners |
| Jonathan Aschoff | Roth Capital Partners |